Cognition Therapeutics (NASDAQ:CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in ...

Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead ...

WASHINGTON, D.C. — On Friday, dozens of dignitaries are scheduled to meet at the White House for a roundtable chaired by President Donald Trump to explore solutions for a college sports industry that ...

The Chancellor delivered her Spring Statement this afternoon, against the backdrop of an escalating conflict across the Middle East. Rachel Reeves claimed her growth plan was working, taking credit ...

Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo ...

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, ...

The outcome of the Scottish Parliament election on 7 May will determine who has responsibility for delivering major public services like health and education over the next five years. But what issues ...

Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 ...

Which factors have the biggest impact on a brand's reputation? To find out, researchers at Reputation Leaders conducted a survey in February 2025 among a nationally representative group of 922 adults ...

The Haywood Highsmith signing was one to get excited about for Suns fans. Although he hadn't played all season due to injury and was cut by the Brooklyn Nets, he had already proven in previous years ...